Hepatitis B antigen and antibody in heroin users

Area of Science:

• Hepatology
• Infectious Diseases
• Public Health

Background:

• Hepatitis B virus (HBV) poses a significant global health risk.
• Heroin use, particularly intravenous administration, is a known risk factor for HBV transmission.
• Understanding HBV seroprevalence in different modes of heroin use is crucial for targeted prevention strategies.

Purpose of the Study:

• To determine the seroprevalence of Hepatitis B surface antigen (HBsAg) and antibodies (anti-HBsAg) in asymptomatic heroin users.
• To compare HBV seromarkers between intravenous and nonintravenous heroin users.
• To compare HBV seromarkers in heroin users against a control group.

Main Methods:

• Assayed Hepatitis B surface antigen (HBsAg) and anti-HBsAg in 442 asymptomatic heroin users and 246 controls.
• Categorized heroin users into intravenous (n=124) and nonintravenous (n=318) groups.
• Statistical analysis to compare seroprevalence rates between groups.

Main Results:

• Heroin users showed significantly higher HBsAg (5.2%) and anti-HBsAg (26.7%) positivity than controls (1.2% and 11.4%, respectively).
• HBsAg positivity did not differ significantly between intravenous (6.5%) and nonintravenous (4.7%) users.
• Anti-HBsAg positivity was significantly higher in intravenous users (44.4%) compared to nonintravenous users (19.8%).

Conclusions:

• Asymptomatic heroin users have a substantially elevated risk of Hepatitis B virus infection.
• While HBsAg prevalence is similar across modes of use, intravenous administration is associated with a higher rate of past HBV exposure indicated by anti-HBsAg.
• Public health interventions should address HBV risks across all forms of heroin use, with particular attention to intravenous administration.